Navigation Links
Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes
Date:11/9/2012

atients with type 2 diabetes, patients with type 2 diabetes who have had moderate renal impairment, and patients with type 2 diabetes who had or were at high risk for developing cardiovascular disease.

Janssen and its affiliates have rights to canagliflozin through a license agreement with Mitsubishi Tanabe Pharma Corporation. Janssen Pharmaceuticals, Inc. and its affiliates have marketing rights in North America, South America, Europe, Middle East, Africa, Australia, New Zealand, and parts of Asia.

About Janssen

At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen Research & Development, LLC and Janssen Pharmaceuticals, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit http://www.janssenrnd.com for more information.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges in
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/22/2014)... influenced by low exposure to testosterone in the womb, ... men,s testosterone levels may be determined before they are ... the hormone than others is important because testosterone is ... hormone have been linked to obesity, diabetes and heart ... for producing testosterone in adults known as Leydig ...
(Date:4/22/2014)... fiction: In enemy territory, activate your cloaking device. And ... to the immune system. Now scientists at Harvard,s Wyss ... tactics to build the first DNA nanodevices that survive ... the way for smart DNA nanorobots that could use ... doctors can today; target drugs to tumors, or even ...
(Date:4/22/2014)... a clinical trial led by Dana-Farber Cancer Institute ... approved a molecularly targeted drug as second-line treatment ... standard chemotherapy has failed. , The FDA approval ... manufacturer, Lilly Oncology, of Indianapolis. A monoclonal antibody ... sold under the name Cyramza, and is the ...
(Date:4/22/2014)... the University of Toronto say a sleep disorder that ... best current predictor of brain diseases like Parkinson,s and ... not just a precursor but also a critical warning ... says associate professor and lead author Dr. John Peever. ... cent of people with RBD will develop a brain ...
(Date:4/21/2014)... Minn. Acute respiratory distress syndrome is a ... who develop the lung disorder postoperatively are at ... those who survive the syndrome may still bear ... Mayo Clinic-led study is helping physicians better identify ... preventing this dangerous and costly surgical complication. ...
Breaking Medicine News(10 mins):Health News:Cloaked DNA nanodevices survive pilot mission 2Health News:Cloaked DNA nanodevices survive pilot mission 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:Acute respiratory distress syndrome: Study IDs surgical patients at risk 2
... New York, NY (June 6, 2012) A clinical ... molecular therapy called vismodegib (trade name Erivedge), can dramatically ... of new ones, in patients with basal cell nevus ... sometimes hundreds or thousands, of skin cancers on each ...
... In a Phase 2 study presented at the ... Oncology (ASCO), clinical researchers from University Hospitals Case Medical ... to treat gynecologic cancers, shortening radiation treatment time from ... stereotactic body radiotherapy (SBRT), has been used on other ...
... THURSDAY, May 31 (HealthDay News) -- Live chicks and ducklings ... a salmonella outbreak that had sickened 93 people in 23 ... in an update Thursday. Eighteen people have been ... under investigation. Among the reported cases so far, illnesses surfaced ...
... , THURSDAY, May 31 (HealthDay News) -- Meat, ... associated with a fivefold increased risk of immediate gout flare-ups, ... arthritis that often first occurs in the big toe. Anecdotal ... but it hasn,t been clear whether they cause immediate attacks. ...
... , THURSDAY, May 31 (HealthDay News) -- More than ... new government report shows. "Untreated tooth decay is ... Dye, an epidemiologist at the U.S. Centers for Disease ... appears that we haven,t been able to make any ...
... Steven Reinberg HealthDay Reporter , THURSDAY, May 31 ... the United States may be infected with chronic hepatitis B ... come from countries in Asia and Africa, where regular vaccination ... "Hepatitis B is a common infection transmitted at birth or ...
Cached Medicine News:Health News:New drug found effective against rare form of basal cell skin cancer 2Health News:New drug found effective against rare form of basal cell skin cancer 3Health News:University Hospitals Case Medical Center experts present at ASCO Annual Meeting 2Health News:University Hospitals Case Medical Center experts present at ASCO Annual Meeting 3Health News:Ohio Mail-Order Hatchery Now Linked to Salmonella in 23 States 2Health News:Gout Flare-ups Rise Sharply With Certain Foods: Study 2Health News:1 in 5 Americans Has Untreated Cavities: CDC 2Health News:Hepatitis B Infection Rates in U.S. Higher Than Thought 2Health News:Hepatitis B Infection Rates in U.S. Higher Than Thought 3
Inquire...
Rapid Urease test for the presumptive identification of H. pylori in gastric mucosal biopsies...
... The QuickVue H.pylori gII test is a ... qualitative detection of IgG antibodies specific to ... whole blood. It utilizes a convenient, non-invasive, ... aid physicians in the diagnosis of H.pylori ...
... a visually read, qualitative immunochromatographic method for ... a bacterium that grows in the stomach ... and some gastric cancers. FlexSure HP, available ... serum samples, provides the physician with the ...
Medicine Products: